DiaRem2: Incorporating duration of diabetes to improve prediction of diabetes remission after metabolic surgery
The DiaRem score was designed to provide a simple, preoperative tool for predicting the likelihood of type 2 diabetes (T2D) remission after Roux-en-Y gastric bypass (RYGB) surgery [1]. The original version of DiaRem (hereafter referred to as DiaRem) used components that are usually known to patients with T2D and their providers, including age, hemoglobin A1C level (HbA1C), and types of T2D medications, compared with other prediction tools, DiaRem is easy to use, has the lowest prediction error [2] and it has been validated in multiple and varied RYGB cohorts [3 –7].
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Christopher D. Still, Peter Benotti, Tooraj Mirshahi, Adam Cook, G. Craig Wood Tags: Original article Source Type: research
More News: Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Gastric Bypass | Gastroenterology | Obesity | Surgery